Table 1. Percentage of resistant Staphylococcus aureus isolated from patients with a range of infections in Aseer Region. (n=210).
| Antimicrobial agents | Resistant isolates (%) |
|---|---|
| 1. Amikacin (30 µg) | 23.5% |
| 2. Amoxicillin (10 µg) | 75.5% |
| 3. Ampicillin (10 µg) | 75.5% |
| 4. Augmentin (30 µg) | 38% |
| 5. Aztreonam (30 µg) | 100% |
| 6. Bacitracin (10 IU) | 17.5% |
| 7. Carbenicillin (00 µg) | 42% |
| 8. Cefepime (30 µg) | 31% |
| 9. Cefotaxime (30 µg) | 31% |
| 10. Cefoxitin (30 µg) | 33% |
| 11. Ceftazidime (30 ug) | 91% |
| 12. Ceftriaxone (30 µg) | 36.5% |
| 13. Cephalothin (30 µg) | 21.5% |
| 14. Cephradine (30 ug) | 34.5% |
| 15. Chloramphenicol (30 µg) | 1.5% |
| 16. Ciprofloxacin (01 µg) | 24% |
| 17. Clindamycin (2 µg) | 24.5% |
| 18. Colistin (10 µg) | 100% |
| 19. Co-trimoxazole (25 µg) | 27% |
| 20. Doxycycline (30 µg) | 15.5% |
| 21. Erythromycin (15 µg) | 21.5% |
| 22. Fusidic acid (30 µg) | 35% |
| 23. Gentamicin (10 µg) | 29% |
| 24. Imipenem (10 µg) | 22.5% |
| 25. Mecillinam (33 µg) | 100% |
| 26. Methicillin (25 µg) | 43.5% |
| 27. Metronidazole (5 µg) | 100% |
| 28. Nalidixic acid (30 µg) | 100% |
| 29. Neomycin (30 µg) | 33.5% |
| 30. Netilmicin (30 µg) | 22.5% |
| 31. Nitrofurantoin (300 µg) | 0% |
| 32. Norfloxacin (10 µg) | 25.5% |
| 33. Novobiocin (30 µg) | 0% |
| 34. Oxacillin (10 µg) | 43.5% |
| 35. Oxytetracycline (30 µg) | 24% |
| 36. Penicillin G (10 IU) | 87.5% |
| 37. Piperacillin (100 µg) | 54.5% |
| 38. Polymyxin B (300 IU) | 100% |
| 39. Rifampicin (05 µg) | 11% |
| 40. Tetracycline (30 µg) | 27.5% |
| 41. Ticarcillin (75 µg) | 36.5% |
| 42. Tobramycin (10 µg) | 29.5% |
| 43. Trimethoprim-sulfamethoxazole (25 µg) | 26% |
| 44. Vancomycin (30 µg) | 0% |